Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$380.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Supernus Pharmaceuticals Inc Announces Pricing Of Public Offering
Supernus Pharmaceuticals Inc announced the pricing of the underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. Supernus has granted the underwriters a 30-day option to purchase up to 900,000 additional shares to cover over-allotments, if any. Jefferies & Company, Inc., Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel Nicolaus Weisel and Lazard Capital Markets LLC are acting as co-managers.
Latest Developments for Supernus Pharmaceuticals Inc
- Supernus Pharmaceuticals Inc Announces Positive Phase IIb Results on SPN-810 and Decision to Advance to Late Stage Development
- Supernus Pharmaceuticals Inc Receives Three Years of Market Exclusivity for Oxtellar XR
- Supernus Pharmaceuticals Inc Receives Tentative Approval of Trokendi XR From FDA
- Supernus Pharmaceuticals Inc Announces Pricing Of Initial Public Offering
Latest Key Developments in Pharmaceuticals
- Wai Yuen Tong Medicine Holdings Ltd Comments On FY 2013 Earnings Guidance
- Astellas Pharma Inc Receives Marketing Authorization for VESOMNI from The Netherlands Medicines Evaluation Board
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- BTG Plc Announces Proposed Placing Of New Ordinary Shares
- Share this
- Link this
- Digg this
Follow Reuters